Bupropion

Generic Name
Bupropion
Brand Names
Aplenzin, Auvelity, Budeprion, Contrave, Forfivo, Wellbutrin, Zyban
Drug Type
Small Molecule
Chemical Formula
C13H18ClNO
CAS Number
34911-55-2
Unique Ingredient Identifier
01ZG3TPX31
Background

Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the upta...

Indication

Bupropion is indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation.
...

Associated Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Major Depressive Disorder (MDD), Obesity, Seasonal Affective Disorder (SAD)
Associated Therapies
Smoking, Cessation, Weight Loss
Clinical Trials
Related News

PET Imaging Study on Occupancy of Dopamine D2 Receptors and Genotypes After Bupropion Administration

Phase 4
Completed
Conditions
Smoking
Interventions
Drug: Bupropion
First Posted Date
2009-02-18
Last Posted Date
2011-02-23
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
12
Registration Number
NCT00846339
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Study of Medical Treatment for Methamphetamine Addiction

First Posted Date
2009-02-02
Last Posted Date
2014-02-26
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
84
Registration Number
NCT00833443
Locations
🇺🇸

UCLA Clinical Research Site 910 Vine St, Los Angeles, California, United States

Comparative Study of SR Bupropion for Adolescent Smoking Cessation

Not Applicable
Conditions
Smoking
Smoking Cessation
Interventions
Drug: Bupropion
Drug: Placebo
First Posted Date
2009-01-08
Last Posted Date
2009-01-08
Lead Sponsor
Geha Mental Health Center
Target Recruit Count
80
Registration Number
NCT00819078
Locations
🇮🇱

Geha Mental Health Center, Petah Tiqva, Israel

Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence

First Posted Date
2008-09-09
Last Posted Date
2020-11-23
Lead Sponsor
University of Minnesota
Target Recruit Count
121
Registration Number
NCT00749658
Locations
🇺🇸

University of Minnesota, Tobacco Use Research Center, Minneapolis, Minnesota, United States

Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

Phase 2
Completed
Conditions
Methamphetamine Dependence
Interventions
Other: Placebo
Drug: Bupropion
First Posted Date
2008-06-02
Last Posted Date
2017-03-21
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
200
Registration Number
NCT00687713
Locations
🇺🇸

Matrix Institute, Woodland Hills, California, United States

🇺🇸

New York University, New York, New York, United States

🇺🇸

UCLA Integrated Substance Abuse Program, Los Angeles, California, United States

and more 9 locations

A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects

First Posted Date
2008-02-28
Last Posted Date
2017-08-24
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
27
Registration Number
NCT00625859
Locations
🇺🇸

GSK Investigational Site, Buffalo, New York, United States

Bupropion and Restless Legs Syndrome

Phase 2
Completed
Conditions
Restless Legs Syndrome
Interventions
Drug: Bupropion
Drug: Placebo
First Posted Date
2008-02-22
Last Posted Date
2019-03-06
Lead Sponsor
East Tennessee State University
Target Recruit Count
60
Registration Number
NCT00621517
Locations
🇺🇸

East Tennessee State University, Johnson City, Tennessee, United States

Effect of Antidepressants on Sex Hormone Levels and Sexual Functioning

Phase 4
Completed
Conditions
Healthy
Interventions
Drug: Fluoxetine
Drug: Bupropion
First Posted Date
2008-02-11
Last Posted Date
2020-12-10
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
83
Registration Number
NCT00611975

A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Affective Disorder

Phase 1
Completed
Conditions
Bipolar Disorder
Interventions
Drug: Bupropion
Drug: Placebo
First Posted Date
2008-01-14
Last Posted Date
2017-01-11
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
5
Registration Number
NCT00593099
Locations
🇺🇸

Connecticut Mental Health Center, New Haven, Connecticut, United States

The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior

First Posted Date
2007-12-27
Last Posted Date
2018-02-08
Lead Sponsor
Yale University
Target Recruit Count
62
Registration Number
NCT00580853
Locations
🇺🇸

Yale Center for Clinical Investigation, Yale University, New Haven, Connecticut, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy